{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG+Oral+Tablet&page=3", "query": { "intervention": "Baricitinib 4 MG Oral Tablet", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 67, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG+Oral+Tablet&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG+Oral+Tablet&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T11:14:22.212Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05858515", "title": "REVERSE-Long COVID-19 With Baricitinib Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post-Acute COVID-19 Syndrome" ], "interventions": [ { "name": "Baricitinib 4 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-10-21", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 6, "location_summary": "San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05858515" }, { "nct_id": "NCT05849038", "title": "Inflammation and Depression in People With HIV", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Depression", "Anhedonia" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2023-12-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05849038" }, { "nct_id": "NCT01299285", "title": "Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "LY3009104", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 6, "start_date": "2011-02", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01299285" }, { "nct_id": "NCT04401579", "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1033, "start_date": "2020-05-08", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401579" }, { "nct_id": "NCT02708095", "title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2016-03-24", "completion_date": "2017-11-09", "has_results": true, "last_update_posted_date": "2018-11-21", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 27, "location_summary": "Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02708095" }, { "nct_id": "NCT01185353", "title": "A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "LY3009104", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 301, "start_date": "2010-10", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-06-16", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 31, "location_summary": "Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Westlake Village", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185353" }, { "nct_id": "NCT01721044", "title": "A Moderate to Severe Rheumatoid Arthritis Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 527, "start_date": "2013-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 32, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721044" }, { "nct_id": "NCT04373044", "title": "Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-05-01", "completion_date": "2021-05-12", "has_results": false, "last_update_posted_date": "2021-05-26", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04373044" }, { "nct_id": "NCT03414502", "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 400, "start_date": "2007-12-10", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414502" }, { "nct_id": "NCT06868381", "title": "A Trial of Baricitinib in Patients With Cardiac Sarcoidosis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cardiac Sarcoidosis" ], "interventions": [ { "name": "Baricitinib (LY3009104) 4 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2026-04-01", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-12T11:14:22.212Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06868381" } ] }